{"id":"NCT00500539","sponsor":"Novartis","briefTitle":"Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.","officialTitle":"An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2007-07-12","resultsPosted":"2011-04-27","lastUpdate":"2011-06-02"},"enrollment":155,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"omalizumab","otherNames":[]}],"arms":[],"summary":"The primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age or older, with no previous exposure to the drug (omalizumab na√Øve patients). The secondary objective of this study is to assess the safety of the liquid formulation of omalizumab in the same patients.","primaryOutcome":{"measure":"The Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up Period","timeFrame":"16 weeks after last dose","effectByArm":[{"arm":"Follow-up Period","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":31,"countries":["United States","Argentina","Germany"]},"refs":{"pmids":["24028677"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":155},"commonTop":["Asthma","Sinusitis","Upper respiratory tract infection","Nasopharyngitis","Headache"]}}